Erytech Pharma SA (ERYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
45
About the Report
About the Report
Summary
Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are intended for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, pancreatic cancer and non hodgkin lymphoma, among others. Erytech provides pipeline products such as eryasp, erymet, erymmune, and others. The company also develops other product candidates which uses encapsulated enzymes to induce tumor starvation. Its technology platform ERYCAPS uses red blood cells to discover therapeutic compounds. Erytech is headquartered in Lyon, France.
Erytech Pharma SA (ERYP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Erytech Pharma SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Erytech Pharma SA, Medical Devices Deals, 2012 to YTD 2018 9
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Erytech Pharma Raises USD3.95 Million in Venture Financing 11
Erytech Pharma Secures USD19.24 Million in Venture Funding 12
Partnerships 13
Erytech Pharma Enters into Research Agreement with Queen's University 13
Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 14
Invetech Enters into Agreement with Erytech Pharma 15
Licensing Agreements 16
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 16
Equity Offering 18
Erytech Pharma Raises USD125 Million in IPO of American Depository Shares 18
Erytech Pharma Raises USD15.9 Million in Private Placement of Shares 20
Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 21
Erytech Pharma Raises USD11 Million in Private Placement of Shares 22
Erytech Pharma Raises USD27 Million in Private Placement of Shares 23
Erytech Pharma Plans to Raise Funds through Public Offering of Shares 25
Erytech Pharma Raises USD38 Million in Private Placement of Shares 26
Erytech Pharma Completes IPO For USD 21 Million 27
Erytech Pharma SA-Key Competitors 29
Erytech Pharma SA-Key Employees 30
Erytech Pharma SA-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Sep 10, 2018: ERYTECH Pharma announces first half of 2018 financial results 32
May 14, 2018: Erytech Reports First Quarter 2018 Financial Results and Provides Business Update 34
Mar 12, 2018: ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017 35
Nov 06, 2017: ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update 37
Sep 11, 2017: ERYTECH Reports First Half 2017 Financial Results and Provides Business Update 38
May 18, 2017: ERYTECH Provides Business Update and Financial Highlights For Q1 2017 41
Clinical Trials 42
Mar 20, 2017: ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017 42
Jan 17, 2017: ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Figure
List of Figures
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Erytech Pharma SA, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
Erytech Pharma SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Erytech Pharma SA, Deals By Therapy Area, 2012 to YTD 2018 8
Erytech Pharma SA, Medical Devices Deals, 2012 to YTD 2018 9
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Erytech Pharma Raises USD3.95 Million in Venture Financing 11
Erytech Pharma Secures USD19.24 Million in Venture Funding 12
Erytech Pharma Enters into Research Agreement with Queen's University 13
Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 14
Invetech Enters into Agreement with Erytech Pharma 15
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 16
Erytech Pharma Raises USD125 Million in IPO of American Depository Shares 18
Erytech Pharma Raises USD15.9 Million in Private Placement of Shares 20
Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 21
Erytech Pharma Raises USD11 Million in Private Placement of Shares 22
Erytech Pharma Raises USD27 Million in Private Placement of Shares 23
Erytech Pharma Plans to Raise Funds through Public Offering of Shares 25
Erytech Pharma Raises USD38 Million in Private Placement of Shares 26
Erytech Pharma Completes IPO For USD 21 Million 27
Erytech Pharma SA, Key Competitors 29
Erytech Pharma SA, Key Employees 30
Erytech Pharma SA, Subsidiaries 31
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.